

Agreement Termination Notice of TAF Sublicense

To: General Counsel of Medicines Patent Pool of Geneva, Switzerland


Dear Sir/Madam,

We thank you very much for giving us the opportunity to participate in the battle against HIV. We have completed Process validation campaign and DMF is ready for filing. Anyhow our company has turned into a Contract Development and Manufacturing Organization (CDMO) currently after couple of years effort starting from decade ago. With more projects move into commercial stage, we have to reduce our Generic APIs portfolio in order to give more capacity to commercialized CDMO projects. In this case we regret to inform you that we apply to terminate the License Agreement of TAF, effected as of 9th April 2018, signed between Zhejiang Langhua Pharmaceutical Co.,Ltd. and THE MEDICINES PATENT POOL FOUNDATION.

We thank you very much for the kind support on this project!

Yours sincerely

Zhejiang Langhua Pharmaceutical Co.,Ltd

Signature: 

Name: Ji Shengbao

Titel: BD Director

Date: 15th Oct 2024



303

1091591443

dhl.com

EXPRESS WORLDWIDE DOX **DHL**

From : Ningbo Nuobai Pharmaceutical Co., Ltd
Rosa Ji
21st Jiangxia Street Ningbo
315000 Zhejiang China
315010 NINGBO
CHINA, PEOPLES REPUBLIC

To : Gilead Sciences, Inc.
General Counsel
333 Lakeside Drive
94404 FOSTER CITY CA
UNITED STATES OF AMERICA

Origin: HGH
Contact: 1

US-JCC-JC1

Content: DOCUMENTATION
Pcs/Shpt Weight Piece
0.5 kg 1/1
Day Time



Ref Code: TSM-APPLV



To: Triplett, Brenda
GILEAD
BLDG: FC309-1
FLR: 09
RM: 279221
Carrier: DHL
10/21/2024 10:59:19 AM
1091591443

EXPRESS WORLDWIDE DOX **DHL**

94404 FOSTER CITY, UNITED STATES OF AMERICA Origin: HGH

US-JCC-JC1

Ref Code: 1091591443CN202410166 Date: 2024-10-16 Pcs/Shpt Weight: 0.5 KG Piece: 1/1

Content Description: DOCUMENTATION

WAYBILL 10 9159 1443

(2L)US94404+42000000

(J) JD01 4600 0117 7654 2938